Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis

Courtney P. Rudick, David L. Cornell, Devendra K. Agrawal

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Sepsis is a disease process characterized by an extreme inflammatory response followed by a period of severe immunosuppression. In recent years, there has been improved survival in the initial immune response during systemic inflammatory response syndrome, and compensatory anti-inflammatory response, yet is mostly unchanged with 18–30% mortality during the later stage of sepsis despite numerous Phase 3 clinical trials. Areas covered: This review article presents a critical evaluation of the most promising newer studies aimed at improving the immunosuppressive stage of sepsis. Administration of DHEA/AED/AET show promise in improving survival. Blockade of signaling pathways for PD-1/PD-L1/CTLA-4, and partial blockade of TREM-1 signaling, and modification to sTREM-1 and the JAK/STAT pathway are promising methods of restoring host immune response and improving survival. While there has been significant progress, currently no findings have been translated into effective clinical interventions. Expert commentary: Clinical success by immunomodulation with individual immune mediator is encouraging and should progress to evaluating combined methods of immunoregulation. Since most of the animal studies do not reproduce human sepsis, development of better animal models and moving toward human studies for intervention will lead to the most beneficial findings in translational science.

Original languageEnglish (US)
Pages (from-to)907-919
Number of pages13
JournalExpert Review of Clinical Immunology
Volume13
Issue number9
DOIs
StatePublished - Sep 2 2017

Fingerprint

Sepsis
Survival
beta-Aminoethyl Isothiourea
Systemic Inflammatory Response Syndrome
Phase III Clinical Trials
Immunomodulation
Dehydroepiandrosterone
Human Development
Immunosuppressive Agents
Immunosuppression
Anti-Inflammatory Agents
Animal Models
Mortality

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. / Rudick, Courtney P.; Cornell, David L.; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 13, No. 9, 02.09.2017, p. 907-919.

Research output: Contribution to journalReview article

@article{6bd889be77de492eb7e68a494b6a78e9,
title = "Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis",
abstract = "Introduction: Sepsis is a disease process characterized by an extreme inflammatory response followed by a period of severe immunosuppression. In recent years, there has been improved survival in the initial immune response during systemic inflammatory response syndrome, and compensatory anti-inflammatory response, yet is mostly unchanged with 18–30{\%} mortality during the later stage of sepsis despite numerous Phase 3 clinical trials. Areas covered: This review article presents a critical evaluation of the most promising newer studies aimed at improving the immunosuppressive stage of sepsis. Administration of DHEA/AED/AET show promise in improving survival. Blockade of signaling pathways for PD-1/PD-L1/CTLA-4, and partial blockade of TREM-1 signaling, and modification to sTREM-1 and the JAK/STAT pathway are promising methods of restoring host immune response and improving survival. While there has been significant progress, currently no findings have been translated into effective clinical interventions. Expert commentary: Clinical success by immunomodulation with individual immune mediator is encouraging and should progress to evaluating combined methods of immunoregulation. Since most of the animal studies do not reproduce human sepsis, development of better animal models and moving toward human studies for intervention will lead to the most beneficial findings in translational science.",
author = "Rudick, {Courtney P.} and Cornell, {David L.} and Agrawal, {Devendra K.}",
year = "2017",
month = "9",
day = "2",
doi = "10.1080/1744666X.2017.1357469",
language = "English (US)",
volume = "13",
pages = "907--919",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis

AU - Rudick, Courtney P.

AU - Cornell, David L.

AU - Agrawal, Devendra K.

PY - 2017/9/2

Y1 - 2017/9/2

N2 - Introduction: Sepsis is a disease process characterized by an extreme inflammatory response followed by a period of severe immunosuppression. In recent years, there has been improved survival in the initial immune response during systemic inflammatory response syndrome, and compensatory anti-inflammatory response, yet is mostly unchanged with 18–30% mortality during the later stage of sepsis despite numerous Phase 3 clinical trials. Areas covered: This review article presents a critical evaluation of the most promising newer studies aimed at improving the immunosuppressive stage of sepsis. Administration of DHEA/AED/AET show promise in improving survival. Blockade of signaling pathways for PD-1/PD-L1/CTLA-4, and partial blockade of TREM-1 signaling, and modification to sTREM-1 and the JAK/STAT pathway are promising methods of restoring host immune response and improving survival. While there has been significant progress, currently no findings have been translated into effective clinical interventions. Expert commentary: Clinical success by immunomodulation with individual immune mediator is encouraging and should progress to evaluating combined methods of immunoregulation. Since most of the animal studies do not reproduce human sepsis, development of better animal models and moving toward human studies for intervention will lead to the most beneficial findings in translational science.

AB - Introduction: Sepsis is a disease process characterized by an extreme inflammatory response followed by a period of severe immunosuppression. In recent years, there has been improved survival in the initial immune response during systemic inflammatory response syndrome, and compensatory anti-inflammatory response, yet is mostly unchanged with 18–30% mortality during the later stage of sepsis despite numerous Phase 3 clinical trials. Areas covered: This review article presents a critical evaluation of the most promising newer studies aimed at improving the immunosuppressive stage of sepsis. Administration of DHEA/AED/AET show promise in improving survival. Blockade of signaling pathways for PD-1/PD-L1/CTLA-4, and partial blockade of TREM-1 signaling, and modification to sTREM-1 and the JAK/STAT pathway are promising methods of restoring host immune response and improving survival. While there has been significant progress, currently no findings have been translated into effective clinical interventions. Expert commentary: Clinical success by immunomodulation with individual immune mediator is encouraging and should progress to evaluating combined methods of immunoregulation. Since most of the animal studies do not reproduce human sepsis, development of better animal models and moving toward human studies for intervention will lead to the most beneficial findings in translational science.

UR - http://www.scopus.com/inward/record.url?scp=85028621438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028621438&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2017.1357469

DO - 10.1080/1744666X.2017.1357469

M3 - Review article

VL - 13

SP - 907

EP - 919

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 9

ER -